Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: In vitro studies in multidrug-resistant breast tumor cells

Journal of Nuclear Medicine

Volumn 37, Issue 9, 1996, Pages 1578-1582

  Ballinger, James R ^a   Bannerman, James ^b   Boxen, Izzie ^b   Firby, Patricia ^b   Hartman, Neil G ^b   Moore, Malcolm J ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NONE

Author keywords

multidrug resistance; technetium 99m sestamibi; technetium 99m tetrofosmin

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TETROFOSMIN TC 99M; VALSPODAR; VERAPAMIL;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DETERMINATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; P-GLYCOPROTEIN; RATS; TECHNETIUM TC 99M SESTAMIBI; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0029762289     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bradley G, Juranka PF, Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta 1988;948:87-128.
2. Erlichman C, Moore MJ, Thiessen JJ, et al. Phase I pharmacokinetic study of cyclosporin A modulation of doxorubicin. Cancer Res 1993;53:4837-4842.
3. Moretti J-L, Caglar M, Duran-Cordobes M, Morere J-F. Can nuclear medicine predict response to chemotherapy? Eur J Nucl Med 1995;22:97-100.
4. Waxman AD. Thallium-201 in nuclear oncology. In: Freeman LM, ed. Nuclear medicine annual 1991. New York: Raven; 1991:193-209.
5. Piwnica-Worms D, Holman BL. Noncardiac applications of hexakis(alkylisonitrile) technetium-99m complexes. J Nucl Med 1990;31:1166-1167.
6. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Career Res 1993;53:977-984.
7. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 1994;35:510-515.
8. Ballinger JR, Hua HA, Berry BW, Firby P, Boxen I. Technetium-99m-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumor cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995;16:253-257.
9. 201Tl-thallous chloride in tumor cells: role of P-glycoprotein. J Nucl Biol Med 1995:in press.
10. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, Lorenz WJ, Maier-Borst W, van Kaick G. Evaluation of tumor metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995;22:434-442.
11. Moretti JL, Caglar M, Boaziz C, Caillat-Vigneron N, Morere JF. Sequential functional imaging with technetium-99m hexakis-2-methoxyisobutylisonitrile and indium-111 octreotide: can we predict the response to chemotherapy in small cell lung cancer? Eur J Nucl Med 1995;22:177-180.
12. Ciarmiello A, Del Vecchio S, Potena MI, et al. Technetium-99m-sestamibi efflux and P-glycoprotein expression in human breast carcinoma [Abstract]. J Nucl Med 1995; 36(suppl):129P.
13. 99mTc-sestamibi [Abstract]. J Nucl Med 1995;36(suppl):129P.
14. Varrella P, Lastoria S, Vergara E, Acampa W, Maurea S, Salvatore M. Technetium-99m-MIBI scintimammography for monitoring tumor response in patients with advanced breast cancer [Abstract]. J Nucl Med 1995;36(suppl):193P.
15. 99mTc-sestamibi in patients with recurrent malignant lymphomas [Abstract]. J Nucl Med 1995;36(suppl):216P.
16. Kelly JD, Forster AM, Higley B, et al. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 1993;34:222-227.
17. 201Tl: a preliminary report [Abstract]. Eur J Nucl Med 1994;21:S16.
18. Mansi L, Rambaldi PF, La Provitera A, Di Gregorio F, Procaccini E. Technetium-99m-tetrofosmin uptake in breast tumors [Abstract]. J Nucl Med 1995;36:83P.
19. Basoglu T, Sahin M, Coskun C, Koparan A, Bernay I, Erkan L. Technetium-99m-tetrofosmin uptake in malignant lung tumors. Eur J Nucl Med 1995;22:687-689.
20. Klain M, Maurea S, Lastoria S, Cuocolo A, Colao A, Salvatore M. Technetium-99m-tetrofosmin imaging of differentiated mixed thyroid cancer. J Nucl Med 1995;36: 2248-2251.
21. Gros P, Talbot F, Tang-Wai D, Bibi E, Kaback HR. Lipophilic cations: a group of model substrates for the multidrug-resistance transporter. Biochemistry 1992;31:1992-1998.
22. Schecter RL, Woo A, Duong M, Batist G. In vivo and in vitro mechanisms of drug resistance in rat mammary carcinoma model. Cancer Res 1991;51:1434-1442.
23. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986;261:15544-15549.
24. Ballinger JR, Cowan DSM, Boxen I, Zhang ZM, Rauth AM. Effect of hypoxia on the accumulation of technetium-99m-glucarate and technetium-99m-gluconate by Chinese hamster ovary cells in vitro. J Nucl Med 1993;34:242-245.
25. 99mTc-sestamibi accumulation in P-gp positive and MRP positive cell lines [Abstract]. Proc Am Assoc Cancer Res 1995;36:358.
26. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human cancer cell line. Science 1992;258:1650-1654.
27. Crankshaw CL, Marmion M, Burleigh BD, Deutsch E, Piwnica-Worms D. Non-reducible mixed ligand Tc(III) cations (Q complexes) are recognized as transport substrates by the human multidrug resistance (MDR) P-glycoprotein [Abstract]. J Nucl Med 1995;36(suppl):130P.